ProCE Banner Activity

Phase Ib/II Study of Lenvatinib + Pembrolizumab for Patients With Metastatic Renal Cell Carcinoma: Updated Results

Slideset Download
Conference Coverage
Lenvatinib plus pembrolizumab associated with an ORR of 63% at 24 weeks and tumor size reduction in 29/30 patients.

Released: June 07, 2018

Expiration: June 06, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen